229 related articles for article (PubMed ID: 26185961)
1. Variation in allergen content in sublingual allergen immunotherapy with house dust mites.
Moreno Benítez F; Espinazo Romeu M; Letrán Camacho A; Mas S; García-Cózar FJ; Tabar AI
Allergy; 2015 Nov; 70(11):1413-20. PubMed ID: 26185961
[TBL] [Abstract][Full Text] [Related]
2. Prolonged effect of allergen sublingual immunotherapy for house dust mites in elderly patients.
Bozek A; Starczewska-Dymek L; Jarzab J
Ann Allergy Asthma Immunol; 2017 Jul; 119(1):77-82. PubMed ID: 28668244
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of House Dust Mite Allergens in Sublingual Allergy Tablets Is Highly Dependent on the Formulation.
Ohashi-Doi K; Kito H; Du W; Nakazawa H; Ipsen H; Gudmann P; Lund K
Int Arch Allergy Immunol; 2017; 174(1):26-34. PubMed ID: 28950271
[TBL] [Abstract][Full Text] [Related]
4. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
Calderon MA; Casale TB; Nelson HS; Demoly P
J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
6. Major allergen content consistency of SQ house dust mite sublingual immunotherapy tablets and relevance across geographic regions.
Nolte H; Plunkett G; Grosch K; Larsen JN; Lund K; Bollen M
Ann Allergy Asthma Immunol; 2016 Sep; 117(3):298-303. PubMed ID: 27613464
[TBL] [Abstract][Full Text] [Related]
7. Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis.
Wang ZX; Shi H
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):407-411. PubMed ID: 28585143
[TBL] [Abstract][Full Text] [Related]
8. House dust mite sublingual immunotherapy in allergic rhinitis.
Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
[TBL] [Abstract][Full Text] [Related]
9. House Dust Mite-Specific Sublingual Immunotherapy Prevents the Development of Allergic Inflammation in a Mouse Model of Experimental Asthma.
Hagner S; Rask C; Brimnes J; Andersen PS; Raifer H; Renz H; Garn H
Int Arch Allergy Immunol; 2016; 170(1):22-34. PubMed ID: 27287860
[TBL] [Abstract][Full Text] [Related]
10. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
11. Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre-school children.
Ponce M; Schroeder F; Bannert C; Schmidthaler K; Hansen CS; Lindholm Bøgh K; Soldo R; Tsui SK; Weinhäusel A; Szépfalusi Z; Eiwegger T
Allergy; 2019 Apr; 74(4):780-787. PubMed ID: 30394551
[TBL] [Abstract][Full Text] [Related]
12. Sublingual house dust mite immunotherapy has no impact on decrease of circulating erythrocytes upon airway allergen challenge in allergic rhinitis.
Jordakieva G; Kundi M; Lemell P; Zieglmayer R; Zieglmayer P; Godnic-Cvar J; Jensen-Jarolim E
Sci Rep; 2017 May; 7(1):2555. PubMed ID: 28566688
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for house-dust mite allergy.
Nelson HS
Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
[TBL] [Abstract][Full Text] [Related]
14. Molecular Profile Sensitization to House Dust Mites as an Important Aspect for Predicting the Efficiency of Allergen Immunotherapy.
Rodinkova VV; Yuriev SD; Kryvopustova MV; Mokin VB; Kryzhanovskyi YM; Kurchenko AI
Front Immunol; 2022; 13():848616. PubMed ID: 35392080
[TBL] [Abstract][Full Text] [Related]
15. Early-life house dust mite allergens, childhood mite sensitization, and respiratory outcomes.
Casas L; Sunyer J; Tischer C; Gehring U; Wickman M; Garcia-Esteban R; Lehmann I; Kull I; Reich A; Lau S; Wijga A; Antó JM; Nawrot TS; Heinrich J; Keil T; Torrent M
Allergy; 2015 Jul; 70(7):820-7. PubMed ID: 25858551
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.
Eifan AO; Akkoc T; Yildiz A; Keles S; Ozdemir C; Bahceciler NN; Barlan IB
Clin Exp Allergy; 2010 Jun; 40(6):922-32. PubMed ID: 20100188
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of exposure and sensitization to house dust mites among rhinitis patients in the steppe environment of Inner Mongolia].
Wang YL; Zhao X; Li FH; Lu Y; Tao QL; Lu MP; Cheng L
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2012 Jan; 47(1):19-25. PubMed ID: 22455768
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Effect of Sublingual and Subcutaneous Immunotherapy in Dust Mite-Allergic Children With Asthma/Rhinitis: A 3-Year Prospective Randomized Controlled Trial.
Karakoc-Aydiner E; Eifan AO; Baris S; Gunay E; Akturk E; Akkoc T; Bahceciler NN; Barlan IB
J Investig Allergol Clin Immunol; 2015; 25(5):334-42. PubMed ID: 26727762
[TBL] [Abstract][Full Text] [Related]
20. The Effective Allergenic Reactivity of House Dust Mite Sublingual Immunotherapy Tablets Is Determined by Tablet Formulation.
Kito H; Du W; Nakazawa H; Lund K; Ohashi-Doi K
Biol Pharm Bull; 2019; 42(6):1030-1033. PubMed ID: 31155578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
